Pulsenmore Ltd. Ordinary Shares
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $14.0M
- Price
- $1.89
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.84%
- Volume
- 10.7K
About
Pulsenmore Ltd. specializes in delivering self-scanning ultrasound technology for distant medical diagnosis and health screening throughout Israel and Europe. Its primary offering is the Pulsenmore at-home ultrasound system, which consists of a portable ultrasound unit that attaches to a patient's smartphone. An accompanying mobile application then securely uploads diagnostic images to the cloud for review. Furthermore, a specialized clinician dashboard enables medical professionals to examine stored video recordings or provide real-time guidance during a scan. Founded in 2014, the company is headquartered in Omer, Israel.
Quick stats
Shares outstanding7.4M
Computed float5.4M
Float / shares72.7%
Cash runway (months)20.5
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0002064764
Websitehttps://www.pulsenmore.com
AI Summary
AI-generated1/9
standardbullishregulatory
Pulsenmore Expands Its Fertility Platform into the UK
Pulsenmore completed registration of its Pulsenmore FC home ultrasound system with the UK's MHRA, allowing it to be marketed across the United Kingdom and Northern Ireland. The clearance follows the system's recent European registration under the MDR and represents the company's expansion from pregnancy monitoring into fertility care.
Pulsenmore FC enables women undergoing IVF and fertility preservation to perform vaginal ultrasound scans at home to monitor follicular development and endometrial thickness under remote clinical guidance, reducing repeated clinic visits. It is the company's second product to reach international markets.
Citing HFEA data, the company sizes the UK opportunity at more than 100,000 fertility treatment and storage cycles in 2024, with roughly 53,000 IVF patients and 21,400 IVF births, or 3.2% of all UK births.
Management said it intends to extend Pulsenmore FC into additional countries with significant IVF and fertility preservation cycles, though no UK commercial agreements, pricing, or adoption timelines were disclosed in the release.
Red flags
- Registration enables marketing only -- no commercial agreements, reimbursement terms, or UK revenue targets disclosed
- Early-stage company with limited operating history and no disclosed UK adoption pipeline